Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Tumors, Lymphoma

In brief

This is an open-label, multicenter, dose-escalation, safety, pharmacokinetics, and pharmacodynamics study.

Key facts

Study ID

NCT00345189

Run by

Biogen

People needed

70

Starts

2006-02-01

Expected to finish

2009-04-01

Last updated by the study team

2009-07-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed solid tumor which has failed standard therapies (surgery, radiotherapy, endocrine therapy, chemotherapy) or for which effective therapy is not available
• At least 18 years of age
• Hematology: Absolute neutrophil count (ANC) > 1500 cells/mm3, platelet count > 100,000 cells/mm3 and hemoglobin >= 9 gm/L
• Hepatic: Bilirubin < 1.5 X upper limit of normal (ULN); alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 X ULN. Patients with known liver metastases or liver neoplasms: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5.0 X ULN.
• Renal: Serum creatinine levels < 2.0 mg/dL or creatinine clearance > 60 mL/min
• Coagulation: international normalized ratio (INR) < 1.5 times normal
• Adrenal: Normal plasma cortisol and adrenocorticotropic hormone (ACTH) levels
• Normal electrocardiogram (ECG) with QTc <= 450 msec for men and <= 470 msec for women
• Estimated life expectancy of at least 3 months as determined by the Investigator
• Eastern Cooperative Oncology Group (ECOG) performance status <= 2
• Male and female patients of childbearing potential must practice effective double-barrier contraception during the study and continue contraception for 3 months after their last dose of study drug. Male patients must agree to not have intercourse with pregnant or nursing women during the study and for 3 months after their last dose of study drug, unless using double-barrier contraception. The only exceptions to double-barrier contraception are: Patient or partner is surgically sterile,female patient is postmenopausal for at least 1 year before screening or patient abstains from sexual intercourse, at the discretion of the Investigator

You may not qualify if…

• Pregnant or nursing women, women of child-bearing age not using reliable means of contraception.
• Radiotherapy or chemotherapy within the previous 28 days. Recovery to Grade 1 or less from chemotherapy-induced toxic effect, except alopecia, is required.
• Participation in any investigational drug study within 28 days prior to CNF2024 administration
• Active infection requiring intravenous antibiotic treatment
• Patients with second malignancy requiring active treatment (except hormonal therapy)
• Concurrent severe or uncontrolled medical disease (i.e., systemic infection, diabetes, hypertension, coronary artery disease, congestive heart failure)
• Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis
• Problems with swallowing or malabsorption
• Chronic diarrhea (excess of 2-3 stools/day above normal frequency)
• Gastrointestinal diseases including gastritis, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis
• Major surgery of the stomach or small intestine
• Adrenal dysfunction > Grade 2
• Patients with diabetes (your doctor will discuss if you are eligible for this study)

Where it is running

• Research site — Scottsdale, Arizona, United States
• Research site — New Haven, Connecticut, United States
• Research site — San Antonio, Texas, United States
• Research site — Sutton, Surrey, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.